BioFocus enters collaboration with Michael J. Fox Foundation
Aug 23, 2011BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research, a not-for-profit organization focused on developing therapies for Parkinson's disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson's disease diagnostic test...
BioFocus extends collaboration with Usher III Initiative
Aug 15, 2011BioFocus has announced that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision...
Astellas Pharma and BioFocus sign target discovery agreement
Jun 28, 2011BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelectÂ® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration...
University of Nottingham and BioFocus sign compound management agreement
Apr 19, 2011BioFocus announced today that its Compound Focus, Inc. subsidiary has signed a compound management services agreement with the University of Nottingham, UK. Under the terms of this agreement, Compound Focus will select, source, acquire, perform quality control checks and reformat a compound collection before returning to the Managed Chemical Compound Collection (MCCC) at the University of Nottingham...
BioFocus leads compound library market with innovative business model
Apr 12, 2011BioFocus announced today that it has established an innovative and unique model for the sale of its SoftFocus compound libraries. Going forward, BioFocus will provide a limited number of clients with SoftFocus libraries on a subscription basis only. These libraries are designed to target protein families of particular interest to the subscribers. This shared exclusivity model will allow clients access to high value, novel compounds with limited competition on derived intellectual property...
BioFocus and Almac collaborate to offer fluorescent lifetime assays
Mar 29, 2011BioFocus have announced that it has entered into collaboration with Almac allowing BioFocus customers with compound screening and profiling requirements to access Almac's FLEXYTETM fluorescence lifetime (FLT) assays. Integrating the assay technology allows BioFocus to offer an FLT platform that will complement its current target class capabilities, provide access to previously inaccessible epigenetic targets and offer alternative approaches to fragment-based screens and kinetic profiling...
Lundbeck Research USA, Inc. and BioFocus sign compound management agreement
Feb 1, 2011BioFocus announced today that its Compound Focus, Inc. subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck's liquid chemical library collection, distributing screening sets to high throughput screening centers in both the USA and Europe
Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease
Jan 16, 2011Ono Pharmaceutical Co., Ltd. (Osaka, Japan) and BioFocus (Saffron Walden, UK) announced today that they have signed a collaboration agreement, focused on discovering novel targets in the field of autoimmune disease. Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration. BioFocus will utilize its unique SilenceSelectÂ® target discovery platform to deliver validated targets for Ono's immunology programs. Ono aims to find modulators for these targets and generate novel and innovative drug candidates.
BioFocus extends collaboration with Amgen into 2012
Dec 23, 2010BioFocus announced today that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services. Under the terms of the extended agreement, BioFocus will receive â¬2.0 M ($2.6 M) in research fees for the first year. Additionally, BioFocus is eligible to receive payments of access fees and success-based milestones
BioFocus extends collaboration with Chiesi
Oct 19, 2010BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, announced today that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached â¬2.5 million.
BioFocus and the National Cancer Institute sign compound management agreement
Oct 14, 2010BioFocus announced today that its Compound Focus subsidiary has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million (â¬3.7 M), with two one-year extension options.
BioFocus signs compound management agreement with eMolecules, Inc.
Oct 11, 2010BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services and eMolecules, Inc., the creators of the open-access chemical structure search engine, today announced that they have signed a compound management service agreement. Under the agreement eMolecules has selected Compound Focus, Inc., the BioFocus compound management operation located in South San Francisco, as its preferred partner for client compound order aggregation services.
BioFocus launches new compound libraries
Sep 28, 2010BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, today announced the launch of two new compound libraries, targeting Family C GPCR's and protein-protein interactions.
Argenta expands collaboration with Genentech to include BioFocus
Sep 14, 2010Argenta, a service division of Galapagos NV (Euronext: GLPG), announced today it has signed a contract extension with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos' other service division, BioFocus.
BioFocus and Usher III Initiative, Inc. announce collaboration
Sep 8, 2010BioFocus and the Usher III Initiative, Inc., a not-for-profit organization, announced today that they have embarked on a drug discovery project focused on Usher Syndrome Type III. Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.
BioFocus and University of Bristol enter drug discovery collaboration in chronic pain
Jul 20, 2010BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total contract value for BioFocus could exceed â¬3.3 million in research fees over two years.
NIH extends agreement with BioFocus until end 2012
Jul 13, 2010BioFocus announced today that the U.S. National Institutes of Health (NIH) have extended their agreement for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. According to the terms of this agreement, BioFocus will be eligible to receive up to $8.6 million (â¬7.0 million) over the course of the two year extension.
BioFocus achieves â¬1.6 M in payments
Jan 13, 2010BioFocus announced today that it has achieved success in its oncology target discovery collaboration with Ortho Biotech Oncology Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). The success of the program has resulted in â¬1.6 million in target acceptance payments.
BioFocus launches new microsite
Oct 6, 2009BioFocus has recently launched its new microsite, www.SilenceSelect.com, dedicated to the SilenceSelectÂ® and FLeXSelectÂ® adenoviral technology. With the ability to knock-down or knock-in human genes in primary cells, these collections cover most of the druggable genome.
BioFocus DPI and Procter & Gamble sign compound management agreement
Oct 4, 2009BioFocus DPI announced today that it has signed a three year compound management agreement with Procter & Gamble Co. (P&G). Under the agreement, BioFocus DPI will manage P&Gâs chemical library collection. These services will be provided by BioFocus DPIâs compound management facility in South San Francisco, USA.